Nuveen Asset Management, LLC Seagen Inc. Transaction History

Nuveen Asset Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $436,451 - $492,628	-2,279 Reduced 0.6%	376,106 $79.8 Million
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $266,073 - $292,462	-1,418 Reduced 0.37%	378,385 $72.8 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $45.1 Million - $71.7 Million	-353,170 Reduced 48.18%	379,803 $76.9 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $95.9 Million - $114 Million	-816,835 Reduced 52.71%	732,973 $94.2 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $56 Million - $74.6 Million	-414,003 Reduced 21.08%	1,549,808 $212 Million

Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $60.1 Million - $99.1 Million	552,748 Added 39.17%	1,963,811 $347 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $7.96 Million - $10.5 Million	-66,526 Reduced 4.5%	1,411,063 $200 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $14 Million - $18.7 Million	-98,170 Reduced 6.23%	1,477,589 $228 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $10.8 Million - $12.8 Million	75,510 Added 5.03%	1,575,759 $268 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $25.4 Million - $30.3 Million	-188,379 Reduced 11.16%	1,500,249 $237 Million
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $16.9 Million - $23.5 Million	-122,969 Reduced 6.79%	1,688,628 $234 Million
Q4 2020 May 17, 2021	BUY	$164.63 - $211.93 $6.34 Million - $8.17 Million	38,534 Added 2.17%	1,811,597 $317 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $292 Million - $376 Million	1,773,063 New	1,773,063 $311 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.